DNA Gyrase Subunit B (EC 5.99.1.3) Market
DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, Share and Trend Analysis Report, By Type (GYR-12, DS-2969, VXC-100, VT-12008911, and Others), By Application (Bacterial Infections, Clostridium Diffclie Infections, Klebsiella Pneumoniae Infections, and Others), Forecast Period (2026–2035)
Industry Overview
DNA gyrase subunit B (EC 5.99.1.3) market was valued at $1.6 billion in 2025 and is projected to reach $3.6 billion by 2035, growing at a CAGR of 8.8% during the forecast period (2026-2035). The market is growing due to the rising incidence of antibiotic-resistant bacterial infections, which is driving the need for novel therapeutic targets such as DNA gyrase subunit B inhibitors. Increasing investment in anti-infective drug development by pharmaceutical and biotechnology companies is further supporting pipeline expansion. Regulatory agencies are also encouraging the development of innovative antibiotics through fast-track designations and funding initiatives. Advancements in molecular research and drug discovery technologies are enabling the identification of more effective and selective compounds. In addition, the growing clinical focus on targeted therapies for infections such as Clostridium difficile and Klebsiella pneumoniae is contributing to sustained market progression.
Market Dynamics
Rising Burden of Antibiotic-Resistant Infections Driving Demand for Novel Targets
The market is primarily driven by the increasing clinical burden of drug-resistant bacterial infections, particularly those caused by pathogens such as Clostridium difficile and Klebsiella pneumoniae. Conventional antibiotic classes are losing effectiveness, creating a clear demand for therapies with novel mechanisms of action. DNA gyrase subunit B has emerged as a validated and differentiated target, offering the potential to overcome resistance associated with existing gyrase inhibitors. This has led to greater prioritization of such compounds within anti-infective pipelines. In addition, hospital-acquired infections continue to place pressure on healthcare systems, reinforcing the need for more effective and targeted antibacterial treatments. The growing focus on precision-based infection management is further supporting the adoption of advanced therapeutic approaches.
Increasing R&D Investments and Regulatory Support Strengthening Antibiotic Innovation Pipeline
Sustained investment in antibacterial research and development is another key factor contributing to market growth. Pharmaceutical and biotechnology companies are actively expanding their pipelines with novel gyrase inhibitors supported by improved screening technologies and structure-based drug design. Regulatory bodies are also facilitating antibiotic innovation through incentives such as fast-track approvals and exclusivity benefits, improving the commercial viability of new entrants. Increased collaboration between industry and research institutions is accelerating early-stage discovery and clinical validation. Furthermore, the availability of funding programs dedicated to antimicrobial resistance is enabling smaller firms to advance promising candidates. These combined factors are strengthening the development landscape and supporting steady market expansion.
Market Segmentation
- Based on the type, the market is segmented into GYR-12, DS-2969, VXC-100, VT-12008911, and others.
- Based on the application, the market is segmented into bacterial infections, Clostridium difficile infections, Klebsiella pneumoniae infections, and others.
DS-2969 Segment Leading Pipeline Advancement
DS-2969 is emerging as a leading subsegment due to its advanced clinical positioning and targeted mechanism against resistant bacterial strains. Its development reflects a shift toward precision antibacterial therapies with improved efficacy profiles. Strong involvement from Daiichi Sankyo Company, Limited has supported steady progress through clinical evaluation stages. The segment benefits from increasing regulatory attention toward innovative antibiotics addressing unmet clinical needs. Recent trends indicate growing emphasis on compounds with reduced resistance potential and optimized safety outcomes. Continued pipeline validation and strategic development efforts are reinforcing its position within the market.
Bacterial Infections Segment Driving Clinical Demand
The bacterial infections segment represents the fastest growing area, supported by the rising incidence of drug-resistant infections in clinical settings. Demand for novel therapies targeting critical pathogens is accelerating research and development activities. Key companies such as Pfizer Inc. and Merck & Co., Inc. are actively expanding their anti-infective portfolios. The segment is witnessing increased adoption of targeted treatment approaches aligned with evolving clinical guidelines. Recent developments highlight a focus on broad-spectrum efficacy with improved resistance management. These factors are contributing to sustained growth and heightened investment interest.
Regional Outlook
The global DNA gyrase subunit B (EC 5.99.1.3) market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Demonstrates Strong Innovation-Led Growth
North America continues to show steady progress driven by a well-established pharmaceutical research ecosystem and strong clinical infrastructure. The presence of major players such as Pfizer Inc. and Merck & Co., Inc. supports continuous pipeline advancement in antibacterial therapies. Increased focus on addressing antimicrobial resistance is influencing both public and private sector initiatives. Regulatory support for novel antibiotic development is enabling faster progression of clinical candidates. The region is also witnessing higher adoption of targeted therapies in hospital settings. Ongoing research collaborations and funding programs are further strengthening market expansion.
Asia-Pacific Emerging as a Key Development Hub
Asia-Pacific is gaining momentum due to expanding pharmaceutical capabilities and increasing investment in drug discovery. Countries such as Japan and China are contributing significantly through active clinical research and innovation efforts. Companies like Daiichi Sankyo Company, Limited and Shionogi & Co., Ltd. are playing a central role in advancing antibacterial pipelines. The region benefits from a large patient pool and rising awareness of resistant infections. There is a growing emphasis on developing cost-effective and targeted treatment options. Strengthening regulatory frameworks and cross-border collaborations are supporting sustained market development.
Market Players Outlook
The major companies operating in the global DNA gyrase subunit B (EC 5.99.1.3) market include Daiichi Sankyo Company, Limited , Vertex Pharmaceuticals Incorporated , Pfizer Inc., Merck & Co., Inc. , Shionogi & Co., Ltd. among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global DNA gyrase subunit B (EC 5.99.1.3) Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1.
Report Summary
• Current
Industry Analysis and Growth Potential Outlook
• Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Sales Analysis – Type |
Application | Country ($ Million)
• DNA Gyrase Subunit B (EC 5.99.1.3) Market Sales Performance of Top Countries
1.1
Research Methodology
• Primary
Research Approach
• Secondary Research Approach
1.2
Market Snapshot
2.
Market Overview and Insights
2.1
Scope of the Study
2.2
Analyst Insight & Current Market Trends
2.2.1 Key DNA
Gyrase Subunit B (EC 5.99.1.3) Market Trends
2.2.2 Market Recommendations
2.3
Porter's Five Forces Analysis for the DNA Gyrase Subunit B (EC 5.99.1.3) Market
2.3.1 Competitive
Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
3.
Market Determinants
3.1
Market Drivers
3.1.1 Drivers for
Global DNA Gyrase Subunit B (EC 5.99.1.3) Market: Impact Analysis
3.2
Market Pain Points and Challenges
3.2.1 Restraints
for Global DNA Gyrase Subunit B (EC 5.99.1.3) Market: Impact Analysis
3.3
Market Opportunities
3.3.1
Opportunities for Global DNA Gyrase Subunit B (EC 5.99.1.3) Market: Impact
Analysis
4.
Competitive Landscape
4.1
Competitive Dashboard – DNA Gyrase Subunit B (EC 5.99.1.3) Market Revenue and
Share by Manufacturers
• Product
Comparison Analysis
• Top Market Player Ranking Matrix
4.2
Key Company Analysis
4.2.1 Daiichi
Sankyo Company, Limited
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Vertex
Pharmaceuticals Incorporated
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Pfizer Inc.
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Merck &
Co., Inc.
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Shionogi
& Co., Ltd.
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3
Top Winning Strategies by Market Players
4.3.1 Merger and
Acquisition
4.3.2 Product Launch
4.3.3 Partnership and Collaboration
5.
Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Sales Analysis by Type ($
Million)
5.1 GYR-12
5.2 DS-2969
5.3 VXC-100
5.4 VT-12008911
5.5 Others
6.
Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Sales Analysis by Application
($ Million)
6.1 Bacterial
Infections
6.2 Clostridium difficile Infections
6.3 Klebsiella pneumoniae Infections
6.4 Others
7.
Regional Analysis
7.1
North America DNA Gyrase Subunit B (EC 5.99.1.3) Market Sales Analysis – Type |
Application ($ Million)
7.1.1 United
States
7.1.2 Canada
7.2
Europe DNA Gyrase Subunit B (EC 5.99.1.3) Market Sales Analysis – Type |
Application ($ Million)
7.2.1 UK
7.2.2 Germany
7.2.3 Italy
7.2.4 Spain
7.2.5 France
7.2.6 Russia
7.2.7 Rest of Europe
7.3
Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Market Sales Analysis – Type |
Application ($ Million)
7.3.1 China
7.3.2 Japan
7.3.3 South Korea
7.3.4 India
7.3.5 Australia & New Zealand
7.3.6 ASEAN Countries
7.3.7 Rest of Asia-Pacific
7.4
Rest of the World DNA Gyrase Subunit B (EC 5.99.1.3) Market Sales Analysis –
Type | Application ($ Million)
7.4.1 Latin
America
7.4.2 Middle East and Africa
8.
Company Profiles
8.1 AstraZeneca
plc
?8.1.1 Quick Facts
?8.1.2 Company Overview
?8.1.3 Product Portfolio
?8.1.4 Business Strategies
8.2 Basilea
Pharmaceutica Ltd.
8.3 Debiopharm Group
8.4 Daiichi Sankyo Company, Limited
8.5 Entasis Therapeutics
8.6 Evotec SE
8.7 GlaxoSmithKline plc
8.8 Melinta Therapeutics, Inc.
8.9 Merck & Co., Inc.
8.10 Nabriva Therapeutics plc
8.11 Paratek Pharmaceuticals, Inc.
8.12 Pfizer Inc.
8.13 Polyphor AG
8.14 Roche Holding AG
8.15 Shionogi & Co., Ltd.
8.16 Spexis AG
8.17 Spero Therapeutics, Inc.
8.18 Venatorx Pharmaceuticals, Inc.
8.19 Vertex Pharmaceuticals Incorporated
8.20 WuXi AppTec Co., Ltd.
1. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global GYR-12 DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global DS-2969 DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global VXC-100 DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global VT-12008911 DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Other DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Application, 2025–2035 ($ Million)
8. Global DNA Gyrase Subunit B for Bacterial Infections Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global DNA Gyrase Subunit B for Clostridium difficile Infections Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global DNA Gyrase Subunit B for Klebsiella pneumoniae Infections Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global DNA Gyrase Subunit B for Other Applications Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Region, 2025–2035 ($ Million)
13. North America DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Country, 2025–2035 ($ Million)
14. North America DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Type, 2025–2035 ($ Million)
15. North America DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Application, 2025–2035 ($ Million)
16. Europe DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Country, 2025–2035 ($ Million)
17. Europe DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Type, 2025–2035 ($ Million)
18. Europe DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Application, 2025–2035 ($ Million)
19. Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Country, 2025–2035 ($ Million)
20. Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Type, 2025–2035 ($ Million)
21. Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Application, 2025–2035 ($ Million)
22. Rest of the World DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Region, 2025–2035 ($ Million)
23. Rest of the World DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Type, 2025–2035 ($ Million)
24. Rest of the World DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Application, 2025–2035 ($ Million)
1. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Share by Type, 2025 vs 2035 (%)
2. Global GYR-12 DNA Gyrase Subunit B (EC 5.99.1.3) Market Share by Region, 2025 vs 2035 (%)
3. Global DS-2969 DNA Gyrase Subunit B (EC 5.99.1.3) Market Share by Region, 2025 vs 2035 (%)
4. Global VXC-100 DNA Gyrase Subunit B (EC 5.99.1.3) Market Share by Region, 2025 vs 2035 (%)
5. Global VT-12008911 DNA Gyrase Subunit B (EC 5.99.1.3) Market Share by Region, 2025 vs 2035 (%)
6. Global Other DNA Gyrase Subunit B (EC 5.99.1.3) Market Share by Region, 2025 vs 2035 (%)
7. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Share by Application, 2025 vs 2035 (%)
8. Global DNA Gyrase Subunit B for Bacterial Infections Market Share by Region, 2025 vs 2035 (%)
9. Global DNA Gyrase Subunit B for Clostridium difficile Infections Market Share by Region, 2025 vs 2035 (%)
10. Global DNA Gyrase Subunit B for Klebsiella pneumoniae Infections Market Share by Region, 2025 vs 2035 (%)
11. Global DNA Gyrase Subunit B for Other Applications Market Share by Region, 2025 vs 2035 (%)
12. Global DNA Gyrase Subunit B (EC 5.99.1.3) Market Research and Analysis by Region, 2025–2035 ($ Million)
13. US DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
14. Canada DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
15. UK DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
16. France DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
17. Germany DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
18. Italy DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
19. Spain DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
20. Russia DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
21. Rest of Europe DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
22. India DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
23. China DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
24. Japan DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
25. South Korea DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
26. Australia and New Zealand DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
27. ASEAN Economies DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
28. Rest of Asia-Pacific DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
29. Latin America DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
30. Middle East and Africa DNA Gyrase Subunit B (EC 5.99.1.3) Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
